Skip to main content
SpringerLink
Log in

Potassium channel openers: Clinical applications in ischemic heart disease—Overview of clinical efficacy of nicorandil

  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Summary

Nicorandil is a balanced arterial and venodilator that may also possess cardioprotective properties via its activation of ATP-sensitive potassium channels. It has a number of beneficial hemodynamic effects and has been shown to be effective in treating angina with similar efficacy as the currently available antianginal agents. In addition, it may have useful effects in unstable and variant angina. In this review we examine the hemodynamic effects of nicorandil and discuss the currently available data on its clinical efficacy, both in isolation and in comparison with other agents.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Taira N. Nicorandil as a hybrid between nitrates and potassium channel activators.Am J Cardiol 1989;63:18J-24J.

    PubMed  Google Scholar 

  2. Suryapranata H, Serruys PW, De Feyter PJ, Verdouw PD, Hugenholtz PG. Coronary vasodilatory action after a single dose of nicorandil.Am J Cardiol 1988;61:292–297.

    PubMed  Google Scholar 

  3. Suryapranata H, MacLeod D. Nicorandil and cardiovascular performance in patients with coronary artery disease.J Cardiovasc Pharmacol 1992;20(Suppl 3):S45-S51.

    Google Scholar 

  4. Satoh K, Mori T, Yamada H, et al. Nicorandil as a nitrate, and cromakalim as a potassium channel opener, dilate isolated porcine large coronary arteries in an agonist-nonselective manner.Cardiovasc Drugs Ther 1993;7:691–699.

    PubMed  Google Scholar 

  5. Aizawa T, Ogasawara K, Kato K. Effects of nicorandil on coronary circulation in patients with ischemic heart disease: Comparison with nitroglycerin.J Cardiovasc Pharmacol 1987;10(Suppl 8):S123-S129.

    PubMed  Google Scholar 

  6. Coltart DJ, Signy M. Acute hemodynamics effects of single dose nicorandil in coronary artery disease.Am J Cardiol 1989;63:34J-39J.

    PubMed  Google Scholar 

  7. Murakami M, Takeyama Y, Matsubara H, et al. Effects of intravenous injection of nicorandil on systemic and coronary haemodynamics in patients with old myocardial infarction—a comparative study with nifedipine and ISDN (abstr).Eur Heart J 1989;10(Suppl)426.

    Google Scholar 

  8. Yokota M, Horisawa T, Iwase M, et al. Effects of a new vasodilator, nicorandil, on exercise-induced impairment of left ventricular function in patients with old myocardial infarction.J Cardiovasc Pharmacol 1987;10(Suppl 8):S116-S122.

    Google Scholar 

  9. Solal AC, Jaeger P, Bouthier J, Juliard JM, Dahan M, Gourgon R. Haemodynamic action of nicorandil in chronic congestive heart failure.Am J Cardiol 1989;63:44J-48J.

    PubMed  Google Scholar 

  10. Tice FD, Binkley PF, Cody RJ, et al. Haemodynamic effects of oral nicorandil in congestive heart failure.Am J Cardiol 1990;65:1361–1367.

    PubMed  Google Scholar 

  11. Galie N, Varani E, Maiello L, et al. Usefulness of nicorandil in congestive heart failure.Am J Cardiol 1990;65:343–348.

    PubMed  Google Scholar 

  12. Camm AJ, Maltz MB. A controlled single-dose study of the efficacy, dose response and duration of action of nicorandil in angina pectoris.Am J Cardiol 1989;63:61J-65J.

    PubMed  Google Scholar 

  13. Kato K, Asanoi H, Wakabayashi C, et al. Effect of nicorandil on exercise performance in patients with effort angina: A multicenter trial using a treadmill exercise test.J Cardiovasc Pharmacol 1987;10(Suppl 8):S98-S103.

    PubMed  Google Scholar 

  14. Meany TB, Richardson P, Camm AJ, et al. Exercise capacity after single and twice daily doses of nicorandil in chronic stable angina pectoris.Am J Cardiol 1989;63:66J-70J.

    PubMed  Google Scholar 

  15. Wagner G. Selected issues from an overview on nicorandil: Tolerance, duration of action and long-term efficacy.J Cardiovasc Pharmacol 1992;20(Suppl 3):S86-S92.

    PubMed  Google Scholar 

  16. Döring G. Antianginal and anti-ischemic effects of nicorandil in comparison with isosorbide-5-mononitrate and isosorbide dinitrate: Results from two multicenter, double-blind, randomised studies with stable coronary heart disease patients.J Cardiovasc Pharmacol 1992;20(Suppl 3):S74-S81.

    Google Scholar 

  17. Hughes LO, Rose EL, Lahiri A, Raftery EB. Comparison of nicorandil and atenolol in stable angina pectoris.Am J Cardiol 1990;66:679–682.

    PubMed  Google Scholar 

  18. Di Somma S, Liguori V, Petitto M, et al. A double-blind comparison of nicorandil and metoprolol in stable effort angina pectoris.Cardiovasc Drugs Ther 1993;7:119–123.

    PubMed  Google Scholar 

  19. Meeter K, Kelder JC, Tijssen JGP, et al. Efficacy of nicorandil versus propanolol in mild stable angina pectoris of effort: A long-term double-blind randomized study.J Cardiovasc Pharmacol 1992;20(Suppl 3):S59-S66.

    Google Scholar 

  20. Guermonprez JL, Blin P, Peterlongo F. A double-blind comparison of the long-term efficacy of a potassium channel opener and a calcium antagonist in stable angina pectoris.Eur Heart J 1993;14(Suppl B):30–34.

    Google Scholar 

  21. Kinoshita M, Hashimoto K, Ohbayashi Y, Inoue T, Taguchi H, Mitsunami K. Comparison of antianginal activity of nicorandil, propranolol and diltiazem with reference to the antianginal mechanism.Am J Cardiol 1989;63:71J-74J.

    PubMed  Google Scholar 

  22. Ulvenstam G, Diderholm E, Frithz G, et al. Antianginal and anti-ischaemic efficacy of nicorandil compared with nifedipine in patients with angina pectoris and coronary heart disease; A double-blind, randomized, multicenter study.J Cardiovasc Pharmacol 1992;20(Suppl 3):S67-S73.

    PubMed  Google Scholar 

  23. Kato K, Iinuma H, Hirosawa K, et al. Clinical evaluation of intravenous SG-75 in treatment of unstable angina—a multicenter double-blind comparative study with intravenous ISDN.Rinsho Iyaku 1991;7:2031–2054.

    Google Scholar 

  24. Araki H, Hayata N, Matsuguchi T, Nakamura M. Effects of nicorandil on rest and effort angina unresponsive to combination therapy with a calcium antagonist and oral nitrate.Clin Ther 1987;9:174–182.

    PubMed  Google Scholar 

  25. Kishida H, Murao S. Effect of a new coronary vasodilator, nicorandil, on variant angina pectoris.Clin Pharm Ther 1987;42:166–174.

    Google Scholar 

  26. Lablanche JM, Bauters C, Leroy F, Bertrand ME. Prevention of coronary spasm by nicorandil: Comparison with nifedipine.J Cardiovasc Pharmacol 1992;20(Suppl 3):S82-S85.

    PubMed  Google Scholar 

  27. Gross GJ, Auchampach JA, Maruyama M, Warltier DC, Pieper GM. Cardioprotective effects of nicorandil.J Cardiovasc Pharmacol 1992;20(Suppl 3):S22-S28.

    Google Scholar 

  28. Auchampach JA, Cavero I, Gross GJ. Nicorandil attenuates myocardial dysfunction associated with transient ischaemia by opening ATP-dependent potassium channels.J Cardiovasc Pharmacol 1992b;20:765–771.

    PubMed  Google Scholar 

  29. Kreye V, Lenz T, Pfrunder D, et al. Pharmacological characterization of nicorandil by 86-Rb efflux and isometric vasorelaxation studies in vascular smooth muscle.J Cardiovasc Pharmacol 1992;20(Suppl 3):S8-S12.

    Google Scholar 

  30. Orita H, Shimanuki T, Fukasawa M, et al. Preventive effect of post-ischemic reperfusion injury by terminal nicorandil-Mg cardioplegia. (abstr)Cardiovasc Drugs Ther 1991;5(Suppl 3):366.

    Google Scholar 

  31. Tamura Y, Saito S, Honye J, et al. Cardioprotective effect of nicorandil during percutaneous transluminal coronary angioplasty (abstr).Eur Heart J 1990;11(Suppl):52.

    PubMed  Google Scholar 

  32. Saito S, Tamura Y, Moriuchi M, et al. Comparative efficacy and safety of nitroglycerin, verapamil and nicorandil during coronary angioplasty.J Am Coll Cardiol 1991;17:377a.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiac Medicine, Royal Brompton Hospital, Sydney Street, SW3 6NP, London, UK

    Charles Knight, Henry Purcell & Kim Fox

Authors
  1. Charles Knight
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Henry Purcell
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kim Fox
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Knight, C., Purcell, H. & Fox, K. Potassium channel openers: Clinical applications in ischemic heart disease—Overview of clinical efficacy of nicorandil. Cardiovasc Drug Ther 9 (Suppl 2), 229–236 (1995). https://doi.org/10.1007/BF00878470

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00878470

Key Words

Search

Navigation